Whitehead Institute for Biomedical Research

Other

The Brigham and Women's Hospital, Inc.

Howard Hughes Medical Institute

New England Medical Center Hospitals. Inc.

Cell Genesys, Inc.

Somatix Therapy Corporation

Lori F Rafield

Richard C Mulligan

Lawrence K Cohen

Brad Guild

James M Wilson

Paul David Robbins

Paul B Robbins

Louis K Birinyi

Isabelle Riviere

Allan D Callow

Isabelle Rivi&egrave;re

Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.

Retroviral gene therapy vectors and therapeutic methods based thereon

Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.

Genetic modification of endothelial cells

Growing community of inventors

San Francisco, CA, United States of America

Lori F Rafield